Cargando…

Optimal combination of MYCN differential gene and cellular senescence gene predicts adverse outcomes in patients with neuroblastoma

INTRODUCTION: Neuroblastoma (NB) is a common extracranial tumor in children and is highly heterogeneous. The factors influencing the prognosis of NB are not simple. METHODS: To investigate the effect of cell senescence on the prognosis of NB and tumor immune microenvironment, 498 samples of NB patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Jiaxiong, Wang, Chaoyu, Jin, Yan, Xia, Yuren, Gong, Baocheng, Zhao, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687280/ https://www.ncbi.nlm.nih.gov/pubmed/38035110 http://dx.doi.org/10.3389/fimmu.2023.1309138

Ejemplares similares

Identification of a Five-Gene Signature Derived From MYCN Amplification and Establishment of a Nomogram for Predicting the Prognosis of Neuroblastoma
por: Xia, Yuren, et al.
Publicado: (2021)

MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database
por: Zhang, Peng, et al.
Publicado: (2017)

Identification of hub genes and their correlation with infiltration of immune cells in MYCN positive neuroblastoma based on WGCNA and LASSO algorithm
por: Chen, Ji, et al.
Publicado: (2022)

MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells
por: Guglielmi, L, et al.
Publicado: (2014)

Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn
por: Kobayashi, K, et al.
Publicado: (2013)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas
por: Petrov, Ivan, et al.
Publicado: (2017)

Identification of NCAPG as an Essential Gene for Neuroblastoma Employing CRISPR-Cas9 Screening Database and Experimental Verification
por: Jia, Yubin, et al.
Publicado: (2023)

Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas
por: Santiago, Teresa, et al.
Publicado: (2019)

Ferroptosis vulnerability in MYCN‐driven neuroblastomas
por: Dasgupta, Shayani, et al.
Publicado: (2022)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

MYCN Directly Targets NeuroD1 to Promote Cellular Proliferation in Neuroblastoma
por: Lu, Fangjin, et al.
Publicado: (2022)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma
por: Hasan, Md. Kamrul, et al.
Publicado: (2013)

Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes
por: Kumps, Candy, et al.
Publicado: (2013)

Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma
por: Seier, Johanna A, et al.
Publicado: (2021)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Regulation of MYCN expression in human neuroblastoma cells
por: Jacobs, Joannes FM, et al.
Publicado: (2009)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

MYCN in Neuroblastoma: “Old Wine into New Wineskins”
por: Braoudaki, Maria, et al.
Publicado: (2021)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
por: Tan, Kezhe, et al.
Publicado: (2022)

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma
por: Zhou, Yang, et al.
Publicado: (2023)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry
por: Durbin, Adam D., et al.
Publicado: (2018)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

SOX4 Mediates ATRA-Induced Differentiation in Neuroblastoma Cells
por: Zhang, Dongyang, et al.
Publicado: (2022)

Aryl Hydrocarbon Receptor Downregulates MYCN Expression and Promotes Cell Differentiation of Neuroblastoma
por: Wu, Pei-Yi, et al.
Publicado: (2014)

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma
por: Yagyu, Shigeki, et al.
Publicado: (2016)

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
por: Taschner-Mandl, Sabine, et al.
Publicado: (2015)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g4986dmab85fl7l516duo85kpe